On January 29-31, 2019, the Longevity Therapeutics Summit is happening at the Argonaut Hotel in San Francisco, California. The conference is a great networking opportunity with some leading names in aging research giving talks during the event.

This will be a two-day conference plus a pre-conference workshop hosted by our good friend Kelsey Moody from Ichor Therapeutics. During the workshop, Kelsey will be giving his personal insights into launching and developing a successful biotech company, particularly the challenges faced in the field of rejuvenation biotechnology. This is sure to be a highly informative workshop and well worth your time, especially if you are interested in launching your own company in this field, but even if you are not, it may still prove interesting to learn about this challenging industry.

This conference aims at bringing together leading figures in biology, biotechnology, omics, investment, and other fields in order to discuss how to further accelerate progress in aging research so that the time between basic research and clinical use is as short as possible.

There is an impressive line-up of speakers at the conference, including Dr. João Pedro de Magalhães from the University of Liverpool; Prof. Judith Campisi from the Buck Institute for Research on Aging; Kelsey Moody from Ichor Therapeutics; Dr. Kristen Fortney, the CEO of BioAge Labs; Dr. Aubrey de Grey from the SENS Research Foundation; Prof. Morgan Levine from the Yale School of Medicine; Jim Mellon, the Chairman of Juvenescence; Dr. Alex Zhavoronkov from Insilico Medicine; and many more.

To match the impressive list of speakers, there is an equally interesting and varied range of topics being covered during the two days of the conference, including:

  • Different therapeutic approaches under research and development that involve senescence, mTOR, NAD+ or mitochondrial dysfunction, regenerative medicine, gene therapy, and your blood.
  • Omics and AI for target and drug discovery
  • Preclinical models
  • Biomarkers of aging
  • Delivery challenges in gene and stem cell therapy
  • Clinical development challenges
  • Regulatory aspects
  • Market access and reimbursement considerations
  • Investment and funding

The main agenda of the event, which is available here, gives more details about the talks and the panels that will take place. On the first day, the focus will be on cellular senescence and senolytics, though other topics, such as mitochondrial dysfunction, will be discussed as well; the second day will see a more varied series of speeches about investment in longevity therapeutics, gene therapy, stem cell therapy, biomarkers, preclinical and translational challenges, and more. A full guide to the event can be downloaded here, and you can register your attendance here.

As a bonus for our readers thinking about attending, you can also get 10% off the ticket price by using the code lifespan10. The event should be a superb opportunity to network and listen to some outstanding talks given by some of the best in the industry.

With such a panel of great speakers and an interesting program, the inaugural Longevity Therapeutics 2019 promises to be yet another fantastic event in the landscape of longevity conferences, and there’s no doubt that it will make an important contribution to pushing the whole field forward.

About the author

Steve Hill

As a scientific writer and a devoted advocate of healthy longevity and the technologies to promote them, Steve has provided the community with hundreds of educational articles, interviews, and podcasts, helping the general public to better understand aging and the means to modify its dynamics. His materials can be found at H+ Magazine, Longevity reporter, Psychology Today and Singularity Weblog. He is a co-author of the book “Aging Prevention for All” – a guide for the general public exploring evidence-based means to extend healthy life (in press).
Write a comment:


Your email address will not be published.

Privacy Policy / Terms Of Use

       Powered by MMD